Status:
UNKNOWN
PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer
Lead Sponsor:
Xijing Hospital
Conditions:
Breast Cancer
HER2-positive Breast Cancer
Eligibility:
FEMALE
18-80 years
Phase:
PHASE2
Brief Summary
patients with HER2-positive breast cancer (cT2-3/N0-1/M0) were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertu...
Detailed Description
Upon approval by the Medical Ethics Committee of Xijing Hospital, patients with HER2-positive breast cancer (cT2-3/N0-1/M0) receiving neoadjuvant therapy, were enrolled. The patients were treated with...
Eligibility Criteria
Inclusion
- HER2-positive breast cancer
- cT2-3/N0-1/M0
- aged18-80 years
- receiving neoadjuvant therapy
- ECOGPS score 0 or 1
- Able to understand the test requirements, willing and able to comply with the test and follow-up procedures
- Adequate organ function
Exclusion
- cardiac, hepatic, renal, or psychiatric disease history
- History of other malignancy within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05346107
Start Date
January 1 2020
End Date
December 31 2023
Last Update
April 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital ， Fourth Military Medical University
Xi'an, Shaanxi, China, 710032